Jacek Kubica, Piotr Adamski, Sławomir Dobrzycki, Robert Gajda, Mariusz Gąsior, Marek Gierlotka, Miłosz Jaguszewski, Jacek Legutko, Maciej Lesiak, Eliano Pio Navarese, Piotr Niezgoda, Małgorzata Ostrowska, Tomasz Pawłowski, Agnieszka Tycińska, Julia M Umińska, Adam Witkowski, Robert Gil
Cangrelor is the only intravenous P2Y12 receptor antagonist. It is an adenosine triphosphate analog that selectively, directly, and reversibly binds to the platelet P2Y12 receptors exerting its antiaggregatory effect. Cangrelor is characterized by linear, dose-dependent pharmacokinetics and rapid onset of action providing potent platelet inhibition exceeding 90%. Cangrelor is rapidly metabolized by endothelial endonucleotidase; thus, its half-life is 2.9 to 5.5 min, and its antiplatelet effect subsides within 60 to 90 min...
November 15, 2023: Cardiology Journal